Fig. 2.

ASC-J9® sensitizes bladder cancer cells to Cisplatin, Doxorubicin or Mitomycin C anti-growth activity. a-b BCa cells were plated in 96-well plates to adhere overnight. The following day, the plates were rinsed and 10% serum containing media with designated doses of ASC-J9® (ASC), Cisplatin (Cis), Doxorubicin (Dox), or Mitomycin C (Mito) were added. After 48 h, relative viable cell numbers of J82 (a) and TCC-SUP (b) cells after treating were determined using a XTT assay. Cell numbers were standardized to cells incubated without ASC. c The combination index (CI) of Cis, Dox, or Mito in combined treatment with ASC in J82 or TCC-SUP cells. d-e The relative viability of J82 (d) and TCC-SUP (e) cells to different doses of ASC with Cis, Dox, or Mito treatment. f The combination index (CI) of ASC treatment in combination with Cis, Dox or Mito in J82 or TCC-SUP cells. For (c) and (f), CI = < 1, indicates synergism; CI = 1 indicates an additive effect; and CI = > 1 indicates drug antagonism. Data are presented as mean ± SD